Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

199 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report.
Blasi M, Kazdal D, Thomas M, Christopoulos P, Kriegsmann M, Brandt R, Volckmar AL, Kirchner M, Heußel CP, Stenzinger A, Kuon J. Blasi M, et al. Among authors: kriegsmann m. Case Rep Oncol. 2021 Mar 18;14(1):477-482. doi: 10.1159/000513904. eCollection 2021 Jan-Apr. Case Rep Oncol. 2021. PMID: 33976623 Free PMC article.
[The role of pathology in the diagnostics of CUP syndrome].
Stenzinger A, Kriegsmann M, Weichert W. Stenzinger A, et al. Among authors: kriegsmann m. Radiologe. 2014 Feb;54(2):124-33. doi: 10.1007/s00117-013-2546-x. Radiologe. 2014. PMID: 24463713 Review. German.
Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences.
Kriegsmann M, Endris V, Wolf T, Pfarr N, Stenzinger A, Loibl S, Denkert C, Schneeweiss A, Budczies J, Sinn P, Weichert W. Kriegsmann M, et al. Oncotarget. 2014 Oct 30;5(20):9952-65. doi: 10.18632/oncotarget.2481. Oncotarget. 2014. PMID: 25296970 Free PMC article.
Reliable Entity Subtyping in Non-small Cell Lung Cancer by Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry on Formalin-fixed Paraffin-embedded Tissue Specimens.
Kriegsmann M, Casadonte R, Kriegsmann J, Dienemann H, Schirmacher P, Hendrik Kobarg J, Schwamborn K, Stenzinger A, Warth A, Weichert W. Kriegsmann M, et al. Among authors: kriegsmann j. Mol Cell Proteomics. 2016 Oct;15(10):3081-3089. doi: 10.1074/mcp.M115.057513. Epub 2016 Jul 29. Mol Cell Proteomics. 2016. PMID: 27473201 Free PMC article.
Mutant KIT as imatinib-sensitive target in metastatic sinonasal carcinoma.
Dieter SM, Heining C, Agaimy A, Huebschmann D, Bonekamp D, Hutter B, Ehrenberg KR, Fröhlich M, Schlesner M, Scholl C, Schlemmer HP, Wolf S, Mavratzas A, Jung CS, Gröschel S, von Kalle C, Eils R, Brors B, Penzel R, Kriegsmann M, Reuss DE, Schirmacher P, Stenzinger A, Federspil PA, Weichert W, Glimm H, Fröhling S. Dieter SM, et al. Among authors: kriegsmann m. Ann Oncol. 2017 Jan 1;28(1):142-148. doi: 10.1093/annonc/mdw446. Ann Oncol. 2017. PMID: 27687311 Free article.
Qualitative Comparison Between Carrier-based and Classical Tissue Microarrays.
Lisenko K, Leichsenring J, Zgorzelski C, Longuespée R, Casadonte R, Harms A, Kazdal D, Stenzinger A, Warth A, Kriegsmann M. Lisenko K, et al. Among authors: kriegsmann m. Appl Immunohistochem Mol Morphol. 2017 Oct;25(9):e74-e79. doi: 10.1097/PAI.0000000000000529. Appl Immunohistochem Mol Morphol. 2017. PMID: 28777146
199 results